GU Cancers 2022 | Stereotactic body RT in patients with oligometastatic CRPC undergoing 1L treatment with abiraterone

Name: Stereotactic body RT in patients with oligometastatic CRPC undergoing 1L treatment with abiraterone
Uploaded: 2022-02-18T00:00:00Z
Duration: 39 s

Giulio Francolini • 18 Feb 2022

GU Cancers 2022

Genitourinary Cancer Prostate Cancer Abiraterone

ARTO

Giulio Francolini, MD, University of Florence, Florence, Italy outlines the ARTO trial (NCT03449719), a randomized phase II trial investigating the benefit of adding stereotactic body radiation therapy (SBRT) to the first-line (1L) standard of care (SOC), abiraterone acetate (AA), for patients with oligoprogressive metastatic castration-resistant prostate cancer (oligo-mCRPC). The primary outcome is the rate of prostate-specific antigen (PSA). The preliminary analysis reports on results following a 6-month follow-up in addition to an exploratory analysis of androgen receptor splice variant (ARV7/ARFL) PSA and PSMA expression on circulating tumor cells (CTCs). This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.